Dominari Holdings Inc. (NASDAQ:DOMH) Sees Significant Decrease in Short Interest
by Renee Jackson · The Cerbat GemDominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totaling 574,812 shares, a decrease of 19.2% from the December 31st total of 711,007 shares. Based on an average trading volume of 262,346 shares, the short-interest ratio is currently 2.2 days. Currently, 5.1% of the company’s shares are short sold. Currently, 5.1% of the company’s shares are short sold. Based on an average trading volume of 262,346 shares, the short-interest ratio is currently 2.2 days.
Insiders Place Their Bets
In other Dominari news, COO Christopher Franklin Devall sold 140,000 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $3.82, for a total transaction of $534,800.00. Following the sale, the chief operating officer directly owned 190,702 shares in the company, valued at $728,481.64. This represents a 42.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 225,000 shares of company stock valued at $876,850. Insiders own 29.92% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its holdings in Dominari by 2.9% during the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock worth $361,000 after purchasing an additional 1,866 shares in the last quarter. PFG Investments LLC purchased a new position in shares of Dominari during the 4th quarter worth approximately $53,000. Vanguard Group Inc. raised its position in Dominari by 8.0% in the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock worth $2,452,000 after acquiring an additional 25,694 shares in the last quarter. Jane Street Group LLC acquired a new stake in Dominari in the second quarter valued at $158,000. Finally, Millennium Management LLC acquired a new stake in Dominari in the third quarter valued at $213,000. Institutional investors and hedge funds own 42.48% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the stock. Weiss Ratings cut shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, January 12th. Wall Street Zen cut Dominari from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Dominari has an average rating of “Sell”.
View Our Latest Analysis on DOMH
Dominari Stock Performance
Shares of NASDAQ:DOMH traded up $0.01 during trading hours on Monday, reaching $3.92. The stock had a trading volume of 96,895 shares, compared to its average volume of 180,165. Dominari has a 1 year low of $2.55 and a 1 year high of $13.58. The firm’s 50 day moving average is $4.37 and its 200-day moving average is $5.30. The stock has a market capitalization of $63.58 million, a price-to-earnings ratio of 0.70 and a beta of 0.74.
Dominari Dividend Announcement
The firm also recently declared a dividend, which was paid on Monday, January 26th. Investors of record on Monday, January 5th were issued a $0.445 dividend. The ex-dividend date of this dividend was Monday, January 5th.
Dominari Company Profile
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.